Bank Of America Corp Gt Biopharma, Inc. Transaction History

Bank Of America Corp

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$0.22 - $0.28 $235 - $300	1,072 Added 107200.0%	1,073 $0
Q2 2023 Aug 14, 2023	SELL	$0.22 - $0.55 $7 - $17	-32 Reduced 96.97%	1 $0
Q1 2023 May 12, 2023	SELL	$0.46 - $1.05 $17 - $40	-39 Reduced 54.17%	33 $0
Q4 2022 Feb 10, 2023	BUY	$0.89 - $58.2 $64 - $4,190	72 New	72 $0
Q2 2022 Aug 12, 2022	SELL	$1.64 - $3.11 $13,456 - $25,517	-8,205 Reduced 16.58%	41,282 $123,000
Q1 2022 May 16, 2022	SELL	$2.6 - $3.3 $102,668 - $130,310	-39,488 Reduced 44.38%	49,487 $142,000
Q4 2021 Feb 08, 2022	BUY	$3.05 - $7.08 $7,637 - $17,728	2,504 Added 2.9%	88,975 $272,000
Q3 2021 Nov 15, 2021	BUY	$6.68 - $15.26 $523,772 - $1.2 Million	78,409 Added 972.58%	86,471 $583,000
Q2 2021 Sep 13, 2021	BUY	$7.19 - $18.96 $57,965 - $152,855	8,062 New	8,062 $125,000

564

Ticker GTBP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 32,557,700
Market Cap $81.7M
Description
GT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate th...

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

Stay updated on Bank Of America Corp with notifications on news.